Category: Allgemein
-
Mursla Bio enters the US market with strategic expansion
Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients
-
Mursla Bio presents breakthrough liquid biopsy technology for extracellular vesicles in Cell Press
Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience
-
Mursla Bio helps shape the standardisation of EV-based liquid biopsy for clinical use
Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy
-
Mursla Bio to present at Bio-International 2023
Mursla Bio was selected to present at the largest pharmaceutical and biotech partnering event
-
Mursla Bio invited to Health Tech Showcase at London Stock Exchange
Showcase spotlights Mursla Bio’s first-in-class science and upcoming milestones for flagship product launch
-
Mursla Bio unlocks new biomarker discovery approach in liquid biopsy and precision medicine
Mursla Bio to showcase its novel tissue-specific extracellular vesicle isolation technology at ISEV2023
-
Mursla Bio to present at Bio-Europe Spring 2023
Mursla Bio was selected to present at the largest pharmaceutical and biotech partnering event in Europe this Spring
-
Mursla Bio selected as UK Life Sciences Innovator 2023
Mursla Bio was selected by the UK Department of International Trade to represent UK excellence across the life sciences sector
-
Mursla Bio invited to present at the Festival of Genomics and Biodata
Mursla Bio’s cutting edge expertise in extracellular vesicle biology is to be showcased at the world’s largest genomics event